Post-cancer fatigue “overestimated"

 

Sydney, Australia (April 26, 2012) – Despite widespread belief to the contrary, as few as 6 percent of women experience cancer-related persistent fatigue a year after undergoing treatment for breast cancer, a new study has found.

Prolonged and disabling fatigue is a common side-effect of many cancer treatments, with large numbers of women reporting that cancer-related fatigue persists for many months after treatment ends. Some studies put the figure as high as 50 percent.

 

But a study of breast cancer survivors from a group of collaborating hospitals in Sydney together with staff of the UNSW’s newly established Cancer Survivors’ Centre has found that figure is overstated, with the previously reported high rates of fatigue most likely attributable to factors unrelated to the cancer or its treatment.

 

And while the study, published this month in Journal of Clinical Oncology, looked at breast cancer, the researchers believe the same results would apply to survivors of other cancers.

 

“The good news is that the vast majority of women who have undergone cancer treatment either never experience ongoing debilitating fatigue in the weeks and months after treatment ends or if they do, it passes relatively quickly,” said study author, Professor David Goldstein, from UNSW’s Prince of Wales Clinical School.

 

“This is not to say that cancer-related fatigue is not a problem. It is still one of the main symptoms of cancer and a major side effect of treatment, but people can be reassured that for the vast majority receiving adjuvant treatment, it is not an ongoing or long term debilitating experience,” Professor Goldstein said.

 

The 5-year prospective study followed 218 women with early-stage breast cancer. The women were observed and questioned at three-monthly intervals for a year after treatment and again at five years. A rigorous definition of fatigue was used to rule out any “background” fatigue.

 

The study found the case rate for cancer-related fatigue fell from 31 percent at the end of treatment to 11 percent at six months and 6 percent at 12 months.

 

The findings suggest that previous studies have overestimated the prevalence of cancer-related fatigue and included transient fatigue states associated with unrelated infections, surgery and minor psychiatric disorders and chronic fatigue states attributable to other conditions.

 

The researchers say for the significant minority of people (6%) who do experience ongoing fatigue, attention can now be focussed on early identification and directing resources where they are most needed.

 

The success of cancer treatments and the increasing number of cancer survivors makes finding find better ways to manage survivorship essential. Researchers believe exercise may be one key element.

 

To that end, the UNSW Cancer Survivors’ Centre, in conjunction with one of its partners the UNSW Lifestyle Clinic, has begun trials of a twelve-week intensive program of exercise and cognitive behaviour therapy to help people with established cancer-related fatigue.

 

“Exercise is increasingly being identified as a medicine, potentially even with a dose response, and it may have a very important role as a therapy not only in cancer recovery but also in the treatment process itself,” Professor Goldstein said.

 

UNSW’s Cancer Survivor Centre is the first comprehensive centre in Australia and is also one of very few worldwide to focus on survivors of both childhood and adult cancers.

 


 

Universtity of New South Wales (UNSW), Australia, 26.04.2012 (tB).

MEDICAL NEWS

IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…

SCHMERZ PAINCARE

Hydromorphon Aristo® long ist das führende Präferenzpräparat bei Tumorschmerz
Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln

DIABETES

Wie das Dexom G7 abstrakte Zahlen mit Farben greifbar macht…
Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT

ERNÄHRUNG

Positiver Effekt der grünen Mittelmeerdiät auf die Aorta
Natriumaufnahme und Herz-Kreislaufrisiko
Tierwohl-Fleisch aus Deutschland nur mäßig attraktiv in anderen Ländern
Diät: Gehirn verstärkt Signal an Hungersynapsen
Süßigkeiten verändern unser Gehirn

ONKOLOGIE

Strahlentherapie ist oft ebenso effizient wie die OP: Neues vom…
Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen

MULTIPLE SKLEROSE

Multiple Sklerose: Aktuelle Immunmodulatoren im Vergleich
Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?

PARKINSON

Meilenstein in der Parkinson-Forschung: Neuer Alpha-Synuclein-Test entdeckt die Nervenerkrankung vor…
Neue Erkenntnisse für die Parkinson-Therapie
Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…